Compare WGO & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WGO | PHAT |
|---|---|---|
| Founded | 1958 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 929.1M | 894.0M |
| IPO Year | 1994 | 2019 |
| Metric | WGO | PHAT |
|---|---|---|
| Price | $31.82 | $12.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $42.78 | $19.83 |
| AVG Volume (30 Days) | 547.8K | ★ 1.4M |
| Earning Date | 03-25-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.40% | N/A |
| EPS Growth | ★ 106.82 | 42.72 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,985,674,000.00 | $175,110,000.00 |
| Revenue This Year | $5.10 | $93.04 |
| Revenue Next Year | $4.69 | $58.91 |
| P/E Ratio | $88.75 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $28.40 | $2.35 |
| 52 Week High | $50.16 | $18.31 |
| Indicator | WGO | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 45.33 | 51.15 |
| Support Level | $28.81 | $10.38 |
| Resistance Level | $35.38 | $12.44 |
| Average True Range (ATR) | 1.06 | 1.05 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 41.00 | 63.87 |
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.